Exelixis (NASDAQ:EXEL) Lowered to Neutral Rating by Bank of America
Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities research analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued on Tuesday, Marketbeat reports. They currently have a $39.00 target price on the biotechnology company’s stock, up from their prior target price of $35.00. Bank of […]
More Stories
Jefferies Financial Group Cuts Foghorn Therapeutics (NASDAQ:FHTX) Price Target to $14.00
Foghorn Therapeutics (NASDAQ:FHTX – Free Report) had its price objective decreased by Jefferies Financial Group from $18.00 to $14.00 in...
NeuroOne Medical Technologies (NASDAQ:NMTC) Releases Earnings Results
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.11) EPS for...
TRU Precious Metals (CVE:TRU) Trading Down 25% – Here’s What Happened
TRU Precious Metals Corp. (CVE:TRU – Get Free Report)’s stock price was down 25% during mid-day trading on Thursday ....
Mizuho Cuts Vital Energy (NYSE:VTLE) Price Target to $37.00
Vital Energy (NYSE:VTLE – Free Report) had its price objective decreased by Mizuho from $39.00 to $37.00 in a research...
Versarien (LON:VRS) Shares Up 12.9% – Here’s Why
Versarien plc (LON:VRS – Get Free Report) was up 12.9% on Tuesday . The stock traded as high as GBX...
Arctic Star Exploration (CVE:ADD) Shares Up 50% – What’s Next?
Arctic Star Exploration Corp. (CVE:ADD – Get Free Report)’s stock price traded up 50% during trading on Thursday . The...